Lastly, the intratumoral insertion of a nanofluidic-based drug eluting seed (NDES) is a minimally invasive method to provide sustained local delivery of OX40 and CD40 monoclonal antibodies into breast tumors and to avoid repeated injections in the tumor area. Here, CD40 is linked to neoplasm.